Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film f…
Drug Manufacturers - Specialty & Generic
US, Warren [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Aquestive Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2018 | - | -1.333 | - | 67 | - | -81 | - | -50 | - | -53 | - | 70 |
| 2019 | -2.9600 | -2.440 | 67 | 52 | -61 | -149 | -50 | -38 | -48 | -41 | 72 | 54 |
| 2020 | -2.8700 | -1.534 | 52 | 44 | -72 | -93 | -53 | -33 | -52 | -35 | 64 | 46 |
| 2021 | -1.9400 | -1.524 | 45 | 49 | -65 | -93 | -39 | -36 | -42 | -38 | 55 | 51 |
| 2022 | -2.3600 | -1.046 | 50 | 47 | -90 | -64 | -45 | -33 | -34 | -35 | 53 | 49 |
| 2023 | -1.2400 | -0.125 | 47 | 48 | -60 | -7 | -39 | -34 | -42 | -36 | 52 | 51 |
| 2024 | -0.1300 | -0.437 | 50 | 58 | -7 | -26 | 1 | -41 | -15 | -44 | 31 | 61 |
| 2025 | - | -0.572 | - | 52 | - | -36 | - | -37 | - | -39 | - | 55 |
| 2026 | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F81/td> | - | 2.F81 | - | 2.F81 |
| 2027 | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F91/td> | - | 1.F91 | - | 1.F91 |
| 2028 | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F101/td> | - | 0.F101 | - | 0.F101 |